Anifrolumab Treatment Improves Quality of Life and Decreases Corticosteroid Use in Patients with Systemic Lupus Erythematosus

The study on Anifrolumab treatment for systemic lupus erythematosus (SLE) involved qualitative interviews with 14 patients and electronic medical record data from 16 patients. It found that Anifrolumab improved symptoms such as fatigue, joint pain, sun sensitivity, skin rashes, and hair loss, although these symptoms were still present. Patients reported enhancements in daily activities, emotional well-being, social life, physical activity, concentration, work, and relationships. Additionally, there was a reduction in disease activity and corticosteroid use. The study highlights the positive impact of Anifrolumab on both subjective experiences and clinical outcomes for SLE patients.